Ahren Acquisition Corp. Announces Pricing of $275 million Upsized IPO
Ahren Acquisition Corp. announced the pricing of its initial public offering (IPO) on December 14, 2021, offering 27,500,000 units at $10.00 each. Each unit comprises one Class A ordinary share and one-half warrant, with the latter having an exercise price of $11.50. Trading will commence on Nasdaq under the ticker symbols AHRNU, AHRN, and AHRNW on December 15, 2021. The offering is expected to close on December 17, 2021, subject to customary conditions. The company aims to merge with high-growth technology firms within four key domains: energy, artificial intelligence, genetics, and space.
- Initial public offering of 27,500,000 units at $10.00 each.
- Focus on merging with high-growth firms in technology sectors.
- Leadership by experienced investor Alice Newcombe-Ellis.
- None.
New York, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Ahren Acquisition Corp. (the “Company”), today announced the pricing of its initial public offering of 27,500,000 units, at a price of
Ahren Acquisition Corp. is a blank check company whose business purpose is to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company’s efforts to identify a prospective initial business combination target will initially be focused on high growth, domain leading companies fueled by breakthrough deep technology and/or deep science. The Company believes that it is well positioned to pursue initial business combination opportunities within its four domains of interest: Planet & Efficient Energy; Brain & Artificial Intelligence; Genetics & Platform Technologies; and Space, Robotics & Physics.
The Company’s sponsor is AACS LP, which is an affiliate of Ahren LP (“Ahren”). Ahren is an investment fund that seeks to make transformative investments in companies that have the capacity to penetrate large markets within and among the Company’s four domains of interest and on a global stage. Ahren was founded in 2017 by technology and disruptive healthcare investor and Founding & General Partner Alice Newcombe-Ellis, alongside co-founding Science Partners that have founded companies and/or whose inventions and technologies are today valued in excess of
Citigroup Global Markets, Inc. is the underwriter for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 4,125,000 units at the initial public offering price to cover over-allotments, if any. Citigroup and Lazard Frères & Co., LLC are acting as our financial advisors in connection with this offering.
The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone: 800-831-9146.
A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.
Cautionary Note Concerning Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
# # #
CONTACT:
Investor Relations, Ahren Acquisition Corp. info@ahrenacq.com
FAQ
What is the purpose of Ahren Acquisition Corp.'s IPO?
When will Ahren Acquisition Corp. begin trading on Nasdaq?
What are the components of the units being offered in the IPO?
Who is the underwriter for the Ahren Acquisition Corp. IPO?